Impact of etanercept on the costs of rheumatoid arthritis (RA): results from a French observational study.
Joint Bone Spine
; 75(1): 25-8, 2008 Jan.
Article
en En
| MEDLINE
| ID: mdl-17913554
ABSTRACT
INTRODUCTION:
Economical impact of rheumatoid arthritis (RA) has been widely modified thanks to TNF inhibitors. Our study aims to estimate the impact etanercept prescription, in term of health resources consumption, within a regional cohort of French RA patients.METHODS:
The study included 148 RA patients, with a mean follow-up duration of 343 days before and after etanercept initiation. Data were anonymously collected from ERASME database of French Health Insurance in Midi-Pyrénées region. A patient-by-patient microcosting approach was performed.RESULTS:
The average annual cost per patient, attributable to RA, was 2.8 times higher after treatment by etanercept than before (15,148.57euro versus 5248.95euro). We observed a rise in pharmaceutical costs, from 11.7% of direct medical costs before to 69.7% after etanercept initiation (120.12euro versus 9995.23euro). We observed a small decrease particularly for NSAIDs (142.14euro versus 102.21euro) and physiotherapy (286.40euro versus 138.77euro). Attributable act costs and indirect costs did not differ before and after etanercept initiation.DISCUSSION:
In this short-term study, initiation of etanercept in RA patients did not come along with a decrease of consumption of health resources. Long-term studies are needed to reveal a potential economical advantage as a consequence of the clinical, structural and functional efficacy of anti-TNF.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Artritis Reumatoide
/
Inmunoglobulina G
/
Antirreumáticos
Tipo de estudio:
Health_economic_evaluation
/
Observational_studies
Límite:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
País/Región como asunto:
Europa
Idioma:
En
Revista:
Joint Bone Spine
Asunto de la revista:
REUMATOLOGIA
Año:
2008
Tipo del documento:
Article
País de afiliación:
Francia